Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Retained Earnings: 2014-2025

Historic Retained Earnings for Zevra Therapeutics (ZVRA) over the last 10 years, with Sep 2025 value amounting to -$434.2 million.

  • Zevra Therapeutics' Retained Earnings rose 7.53% to -$434.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$434.2 million, marking a year-over-year increase of 7.53%. This contributed to the annual value of -$505.3 million for FY2024, which is 26.39% down from last year.
  • Per Zevra Therapeutics' latest filing, its Retained Earnings stood at -$434.2 million for Q3 2025, which was down 0.13% from -$433.7 million recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Retained Earnings peaked at -$262.6 million during Q2 2021, and registered a low of -$508.4 million during Q1 2025.
  • For the 3-year period, Zevra Therapeutics' Retained Earnings averaged around -$429.1 million, with its median value being -$433.7 million (2025).
  • In the last 5 years, Zevra Therapeutics' Retained Earnings tumbled by 32.70% in 2022 and then climbed by 7.53% in 2025.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Retained Earnings stood at -$267.0 million in 2021, then slumped by 32.47% to -$353.7 million in 2022, then dropped by 13.02% to -$399.8 million in 2023, then dropped by 26.39% to -$505.3 million in 2024, then increased by 7.53% to -$434.2 million in 2025.
  • Its last three reported values are -$434.2 million in Q3 2025, -$433.7 million for Q2 2025, and -$508.4 million during Q1 2025.